Rifampicin-Mediated Metabolic Changes in Mycobacterium tuberculosis

Area of Science:

• Microbiology
• Metabolomics
• Drug Discovery

Background:

• Mycobacterium tuberculosis (Mtb) is a global pathogen causing millions of tuberculosis cases.
• Rifampicin is a first-line treatment, but Mtb develops resistance mechanisms.
• Understanding Mtb's metabolic response to rifampicin is crucial for effective treatment.

Purpose of the Study:

• To characterize rifampicin-induced metabolic changes in wild-type Mtb.
• To identify metabolic pathways and protein interactors affected by rifampicin.
• To provide a basis for understanding Mtb's physiological response to rifampicin.

Main Methods:

• Metabolomic analysis of wild-type Mtb treated with rifampicin.
• Identification of significantly altered metabolites and associated pathways.
• Prediction of host protein interactors for the dysregulated metabolome.
• Validation of key metabolites using multiple-reaction monitoring.

Main Results:

• 173 metabolites were significantly altered by rifampicin treatment in Mtb.
• Affected pathways include pyrimidine, purine, arginine, phenylalanine, tyrosine, and tryptophan metabolism.
• Predicted protein interactors are involved in transcription, inflammation, apoptosis, proteolysis, and DNA replication.
• Tricarboxylic acid cycle metabolites, arginine, and phosphoenolpyruvate were validated.

Conclusions:

• Rifampicin causes widespread metabolic alterations in Mtb.
• The study identifies key metabolic pathways and potential drug targets.
• These findings enhance understanding of rifampicin's mechanism and hold therapeutic potential for tuberculosis.